List view / Grid view
10 December 2013 | By Boehringer Ingelheim
The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics...
10 December 2013 | By Daiichi Sankyo Company
This analysis of VTE patients with cancer was presented at the 2013 American Society of Hematology Annual Meeting and Exposition...
9 December 2013 | By Johnson & Johnson
Sub-Saharan African Ministries of Health invited to submit expression of interest to participate in new effort donation program to be part of broader initiative to raise awareness and action...
9 December 2013 | By Novartis
Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials...
9 December 2013 | By AstraZeneca
The donation of the facility and its equipment will ensure that the laboratory continues to serve scientific and research purposes...
8 December 2013 | By Gilead Sciences
In this study, single-agent treatment with idelalisib achieved an overall response rate of 57 percent with a median duration of response of 12.5 months...
6 December 2013 | By Novartis
LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma...
6 December 2013 | By AstraZeneca
Fluenz Tetra is a nasally administered four-strain live attenuated influenza vaccine for the prevention of influenza in children and adolescents from 24 months up to 18 years of age...
5 December 2013 | By GlaxoSmithKline
GlaxoSmithKline plc announced the formation of the Oncology Clinical and Translational Consortium...
4 December 2013 | By Nova Laboratories
The product has been granted orphan drug designation by the FDA, a status given to a product intended for the treatment of a rare disease or condition...
4 December 2013 | By Teva Pharmaceutical Industries
Glatiramer acetate for injection is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis...
4 December 2013 | By Novartis
"Cancer treatment has been revolutionized by targeted therapies, which have established a highly successful approach to the management of many cancers..."
4 December 2013 | By AstraZeneca
AstraZeneca announced a ruling by the US District Court for the Southern District of New York which ordered Apotex Corp., Apotex, Inc and Torpharm, Inc...
3 December 2013 | By
XARELTO® is the most prescribed novel oral anticoagulant in the U.S. Market today...
3 December 2013 | By Sareum Holdings plc
Sareum Holdings plc is pleased to announce that it has signed a co-development agreement with Hebei Medical University Biomedical Engineering Center to advance its Aurora+FLT3 cancer programme...
